Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI310 plus sintilimab-based first-line study in unresectable or metastatic hepatocellular carcinoma
CTR20261005Phase 3Active
- Sponsor
- Innovent Biologics
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of IBI310, sintilimab, bevacizumab, oxaliplatin and capecitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Innovent Biologics. Primary endpoints: Objective response rate, Progression-free survival and 2 more. Started Apr 2026; status: active.
02
Drugs
IBI310sintilimabbevacizumaboxaliplatincapecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20261005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261005.